The Renin-Angiotensin-Aldosterone System in Adiposity, Blood Pressure and Glucose in African Americans
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to examine the impact of the Renin-Angiotensin-Aldosterone System
(RAAS) blockade with medications (valsartan) or RAAS and neprilysin inhibition
(valsartan/sacubitril) vs. placebo on changes in blood sugar and insulin secretion from the
pancreas over 26 weeks assessed with glucose clamp studies among African Americans (AAs) with
impaired glucose tolerance.
The investigators hypothesize that combined RAAS/neprilysin inhibition will lead to greater
improvement in insulin release from the pancreas and improved blood sugar compared to RAAS
inhibition alone among AAs with impaired glucose tolerance.
Phase:
Phase 4
Details
Lead Sponsor:
Ohio State University
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan